investig
kinet
serolog
respons
middl
east
respiratori
syndrom
coronaviru
merscov
infect
use
viru
neutral
merscov
igg
elisa
test
patient
robust
antibodi
respons
develop
third
week
ill
delay
antibodi
respons
neutral
test
associ
sever
diseas
patient
demograph
clinic
profil
shown
onlin
technic
appendix
tabl
http
wwwnccdc
patient
sever
diseas
requir
mechan
ventil
requir
supplement
oxygen
die
mild
diseas
serial
serum
sampl
collect
analyz
studi
approv
snu
institut
review
board
antibodi
merscov
detect
use
plaqu
reduct
neutral
test
prnt
merscov
igg
elisa
euroimmun
germani
onlin
technic
appendix
merscov
emc
use
prnt
assay
prnt
endpoint
prnt
use
sensit
prnt
cutoff
detect
mild
infect
elisa
base
recombin
spike
region
strain
emc
region
suffici
diverg
differ
coronaviru
speci
expect
lead
less
crossreact
overal
serolog
respons
robust
detect
patient
week
ill
figur
patient
serum
sampl
test
beyond
day
ill
prnt
titer
day
titer
day
patient
l
woman
underli
diseas
weakli
posit
prnt
borderlin
elisa
respons
optic
densiti
ratio
even
day
ill
chest
radiograph
show
lung
infiltr
oxygendepend
administ
antivir
drug
corticosteroid
recoveri
unev
antibodi
respons
patient
man
delay
day
ill
onset
figur
requir
mechan
ventil
ill
day
given
convalescentphas
plasma
ml
antibodi
titer
unknown
outbreak
index
patient
wife
next
day
antibodi
respons
undetect
patient
serum
prnt
elisa
day
prnt
antibodi
titer
neg
elisa
respons
strong
antibodi
respons
develop
day
onward
hypothes
data
first
day
ill
repres
serolog
respons
unaffect
passiv
transfus
convalescentphas
plasma
day
thu
data
includ
analysi
patient
given
second
infus
convalescentphas
plasma
day
serolog
data
day
exclud
analysi
construct
statist
model
age
sex
incub
period
concomit
condit
therapi
corticosteroid
antivir
drug
adjust
diseas
sever
assess
factor
associ
time
ill
onset
commenc
logphas
antibodi
respons
tabl
time
antibodi
respons
reach
titer
prnt
becom
posit
elisa
onlin
technic
appendix
tabl
acceler
failur
model
use
natur
interpret
median
time
ill
onset
aforement
antibodi
respons
onlin
technic
appendix
increas
antibodi
titer
exhibit
sshape
pattern
assess
rate
chang
antibodi
respons
commenc
exponenti
phase
manual
remov
data
steadi
state
thu
restrict
antibodi
data
logphas
respons
tabl
linear
mix
model
use
test
potenti
differ
rate
increas
factor
onlin
technic
appendix
patient
sever
diseas
signific
delay
commenc
prnt
antibodi
respons
tabl
steeper
slope
antibodi
respons
began
tabl
thu
delay
adapt
immun
respons
may
contribut
increas
sever
passiv
therapi
convalescentphas
immun
plasma
may
clinic
benefici
avian
influenza
viru
infect
human
earlier
antibodi
respons
faster
rate
increas
antibodi
titer
associ
milder
diseas
sarscov
infect
earlier
antibodi
respons
associ
advers
outcom
east
respiratori
syndrom
coronaviru
merscov
infect
day
ill
onset
determin
use
endpoint
plaqu
reduct
neutral
test
prnt
igg
elisa
b
key
indic
individu
patient
red
inic
patient
sever
ill
requir
mechan
ventil
blue
indic
patient
sever
ill
requir
supplement
oxygen
therapi
green
indic
patient
mild
ill
better
present
prnt
titer
jitter
vertic
random
nois
ad
prevent
overplot
ad
random
number
titer
within
rang
log
scale
od
optic
densiti
extens
contact
trace
outbreak
enabl
us
determin
date
merscov
exposur
incub
period
patient
onlin
technic
appendix
tabl
longer
incub
period
associ
earlier
commenc
antibodi
respons
detect
elisa
tabl
onlin
technic
appendix
tabl
steeper
slope
respons
began
tabl
even
adjust
diseas
sever
use
interferon
antivir
drug
associ
earlier
commenc
antibodi
respons
detect
elisa
tabl
time
commenc
respons
similar
men
women
slope
respons
steeper
male
patient
tabl
understand
merscov
antibodi
respons
kinet
help
defin
window
passiv
antibodi
therapi
may
use
studi
window
first
day
ill
patient
howev
patient
may
develop
strong
antibodi
respons
even
week
ill
therapi
must
individu
studi
limit
first
merscov
isol
studi
patient
avail
merscov
emc
basi
serolog
assay
use
strain
emc
clade
viru
outbreak
south
korea
caus
clade
b
viru
howev
use
serum
natur
infect
camel
previous
show
clade
b
virus
genet
divers
merscov
egypt
serolog
indistinguish
anoth
studi
report
isol
merscov
circul
saudi
arabia
antigen
indistinguish
emc
strain
neutral
test
human
convalescentphas
serum
thu
unlik
use
merscov
emc
studi
consider
affect
observ
antibodi
titer
second
limit
small
number
patient
studi
n
follow
acut
stage
ill
longer
term
followup
need
defin
durat
antibodi
respons
merscov
antibodi
respons
wane
report
sar
relev
interpret
seroepidemiolog
studi
find
convalescentphas
donor
high
antibodi
titer
passiv
immunotherapi
would
use
investig
igm
antibodi
respons
antibodi
respons
viru
protein
includ
merscov
nucleoprotein
especi
patient
l
poor
antibodi
respons
summari
find
show
earli
merscov
antibodi
respons
associ
reduc
diseas
sever
robust
neutral
elisa
igg
antibodi
respons
mount
third
week
ill
patient
howev
robust
respons
occur
patient
infect
patient
may
undetect
serolog
seroepidemiolog
method
differ
rate
chang
p
valu
estim
use
linear
mix
model
posit
valu
indic
faster
increas
antibodi
titer
given
antibodi
titer
exhibit
sshape
pattern
analysi
restrict
data
logphas
antibodi
respons
manual
remov
data
inductivesteadyst
phase
increas
antibodi
titer
log
phase
compar
differ
factor
adjust
diseas
sever
use
linear
mix
model
account
repeat
measur
assum
linear
increas
trend
day
sinc
ill
onset
titer
first
logtransform
base
od
optic
densiti
endpoint
plaqu
reduct
neutral
test
adjust
sever
